- Report
- January 2024
- 119 Pages
Europe
From €3293EUR$3,450USD£2,759GBP
- Report
- January 2024
- 112 Pages
Asia Pacific
From €3293EUR$3,450USD£2,759GBP
- Report
- January 2024
- 110 Pages
North America
From €3293EUR$3,450USD£2,759GBP
- Report
- January 2024
- 95 Pages
Africa, Middle East
From €3293EUR$3,450USD£2,759GBP
- Report
- January 2024
- 92 Pages
From €3293EUR$3,450USD£2,759GBP
- Report
- November 2023
- 185 Pages
Global
From €4247EUR$4,450USD£3,558GBP
From €3293EUR$3,450USD£2,759GBP
- Report
- February 2021
- 108 Pages
Asia Pacific
From €3293EUR$3,450USD£2,759GBP
- Report
- November 2023
- 120 Pages
Asia Pacific
From €3818EUR$4,000USD£3,199GBP
- Report
- December 2022
- 72 Pages
Australia
From €3340EUR$3,500USD£2,799GBP
- Report
- January 2024
- 146 Pages
Global
From €4056EUR$4,250USD£3,398GBP
- Report
- July 2021
- 112 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- March 2024
- 150 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- November 2023
- 176 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- September 2023
- 119 Pages
From €3293EUR$3,450USD£2,759GBP
- Report
- September 2023
- 143 Pages
Europe
From €3293EUR$3,450USD£2,759GBP
- Report
- September 2023
- 216 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- October 2023
- 145 Pages
Global
From €3006EUR$3,150USD£2,519GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more